TrialThe Lancet. Oncology2017

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Daniel V T Catenacci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.